Gene · 51755
Papers3,441
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,441
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In silico Drug Discovery: Bridging the Gaps in Preclinical Translation. | Drug Discov Today | 2026 | 41349903 | PubTator, text mining | PubMed |
| CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement. | Cancer Res | 2026 | 41289556 | PubTator, text mining | PubMed |
| PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications. | Eur Urol Oncol | 2026 | 41219112 | PubTator, text mining | PubMed |
| HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer. | Prostate Cancer Prostatic Dis | 2026 | 41139148 | PubTator, text mining | PubMed |
| Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol. | Int J Cancer | 2026 | 41099623 | PubTator, text mining | PubMed |
| Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer. | J Natl Cancer Inst | 2026 | 41092317 | PubTator, text mining | PubMed |
| Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer. | Prostate | 2026 | 41046457 | PubTator, text mining | PubMed |
Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data. | Int J Surg | 2026 | 40968764 | PubTator, text mining | PubMed |
| MolGlueDB: an online database of molecular glues. | Nucleic Acids Res | 2026 | 40842115 | PubTator, text mining | PubMed |
An Advanced Network Pharmacology Study Reveals the Multi-Pathway and Multi-Gene Regulatory Mechanism of Jinbai Heat-clearing Prescription in HPV-induced Cervical Cancer via Molecular Docking and Microarray Data Analysis. | Curr Med Chem | 2026 | 40798963 | PubTator, text mining | PubMed |
| CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3-Mediated Mitophagy. | Cell Prolif | 2026 | 40605142 | PubTator, text mining | PubMed |
| Precision Medicine in Prostate Cancer with a Focus on Emerging Therapeutic Strategies. | Biomedicines | 2025 | 41595588 | PubTator, text mining | PubMed |
| Successful treatment with sintilimab plus anlotinib for SMARCA4-deficient non-small cell lung cancer withMET exon 14 skipping: a case report. | Nagoya J Med Sci | 2025 | 41550197 | PubTator, text mining | PubMed |
| Targeted next-generation sequencing reveals genomic differences between male and female breast cancer. | Transl Cancer Res | 2025 | 41510123 | PubTator, text mining | PubMed |
| Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas. | Int J Mol Sci | 2025 | 41465280 | PubTator, text mining | PubMed |
| Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis. | Ther Adv Med Oncol | 2025 | 41437938 | PubTator, text mining | PubMed |
| Exploratory Covalent Docking of Michael-Acceptor Natural Products at Reactive Cysteines in Cancer Tyrosine Kinases. | Int J Mol Sci | 2025 | 41373548 | PubTator, text mining | PubMed |
| Geminin inhibits DNA replication licensing by sterically blocking CDT1-MCM2 interactions. | Nat Commun | 2025 | 41365879 | PubTator, text mining | PubMed |
| FeaSion decodes the regulatory landscape and functional diversity of RNA polymerase II CTD phosphorylation. | Sci Adv | 2025 | 41313762 | PubTator, text mining | PubMed |
| Development of FBXO22 Degraders and the Recruitment Ligand 2-Pyridinecarboxyaldehyde (2-PCA). | J Am Chem Soc | 2025 | 41292500 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51755/papers?page=7